This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study


Vedin, Inger, Cederholm, Tommy, Freund-Levi, Yvonne, Basun, Hans, Hjorth, Erik, Irving, Gerd Faxén, Eriksdotter-Jönhagen, Maria, Schultzberg, Marianne, Wahlund, Lars-Olof, Palmblad, Jan


Journal Of Lipid Research, Volume: 51, No.: 5, Pages.: 1179-1185

Year of Publication



Omega-3 fatty acids, e.g., dokosahexaenoic acid (DHA) and eikosapentaenoic acid (EPA), ameliorate inflammatory reactions by various mechanisms, but the role of prostaglandins remains unclear. Our aim was to determine if dietary supplementation with a DHA-rich fish oil influenced the release of PGF(2alpha) from peripheral blood mononuclear cells (PBMC). In the OmegAD study, 174 Alzheimer disease patients received either 1.7 g DHA plus 0.6 g EPA or a placebo daily for six months. PBMCs from the 21 (9 on fish oil and 12 on placebo) first-randomized patients were stimulated with either lipopolysaccharide (LPS) or phytohemagglutinin (PHA) before and after 6 months. Our results showed that plasma concentrations of DHA and EPA increased significantly at 6 months in the omega-3 group. PGF(2alpha) release from LPS- (but not from PHA-) stimulated PBMC was significantly diminished in this group; no change was noted in the placebo group. PGF(2alpha) changes correlated inversely with changes in plasma DHA and EPA. Decreased IL-6 and IL-1(beta) levels correlated with decreased PGF(2alpha) levels. The stimulus-specific PGF(2alpha) release from PBMC after 6 months of oral supplementation with the DHA-rich fish oil might be one event related to reduced inflammatory reactions associated with omega-3 fatty acid intake.;

Bibtex Citation

@article{Vedin_2009, doi = {10.1194/jlr.m002667}, url = {}, year = 2009, month = {nov}, publisher = {American Society for Biochemistry {&} Molecular Biology ({ASBMB})}, volume = {51}, number = {5}, pages = {1179--1185}, author = {I. Vedin and T. Cederholm and Y. Freund-Levi and H. Basun and E. Hjorth and G. F. Irving and M. Eriksdotter-Jonhagen and M. Schultzberg and L. O. Wahlund and J. Palmblad}, title = {Reduced prostaglandin F2$less${IMG} {SRC}="/math/alpha.gif" {ALT}="~" {BORDER}="0 {ALIGN}="{MIDDLE}"$greater$ release from blood mononuclear leukocytes after oral supplementation of ~3 fatty acids: the {OmegAD} study}, journal = {The Journal of Lipid Research} }


acid, administration & dosage, administration oral, aged, aged, 80 and over, alzheimer disease, biosynthesis, blood, culture media conditioned, cytokines, dietary supplements, dinoprost, drug effects, eikosapentaenoic, female, humans, inflammatory, leukocytes mononuclear, lipopolysaccharides, male, metabolism, middle aged, monocytes, pharmacology, phytohemagglutinins, reactions, tlymphocytes

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Herbal remedies, vitamins, dietary supplements